FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57626
News▲ Bullish
Healthcare Data Monetization Market worth $1.3 billion by 2031
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 14:30 UTC
LAST UPDATE2026-09-30 14:30 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A 14.5% CAGR forecast for healthcare data monetization signals a growing niche, though it is projection-based.
Healthcare data monetization forecast, long-dated
CATALYST TO WATCH
Adoption by payers and providers
MAIN RISK
Forecasts may overstate regulatory feasibility
FULL DISPATCH
DELRAY BEACH, Fla., Sept. 30, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Healthcare Data Monetization Market is projected to reach USD 1.3 billion by 2031 from USD 0.7 billion in 2026, at a CAGR of 14.5% during the forecast period. Browse 350 market data Tables and 50...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis2026-09-30 14:30 UTC
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis2026-09-30 14:30 UTC
→CORRELATIONshares Healthcare
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies2026-09-30 14:31 UTC
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies2026-09-30 14:31 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.